You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,862,772


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,862,772
Title:Compositions and methods
Abstract: The invention relates to a composition comprising an anchor region capable of binding to a plasma cell; and a binding region associated with the anchor region, wherein the binding region binds a specific plasma cell antibody.
Inventor(s): Radbruch; Andreas (Berlin, DE), Hiepe; Falk (Berlin, DE), Taddeo; Adriano (Berlin, DE), Gerl; Velia (Berlin, DE), Hoyer; Bimba F. (Berlin, DE), Chang; Hyun-Dong (Berlin, DE), Theiel; Andreas (Berlin, DE)
Assignee: BEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN (DRFZ) (Berlin, DE)
Application Number:14/426,650
Patent Claims:1. A method for the treatment or prevention of a disease caused or exacerbated by an antibody released by a plasma cell comprising delivering to an individual a composition comprising: an anchor region, wherein the anchor region is an antibody, a (Fab').sub.2, monovalent Fab, single chain antibody, single chain Fv (scFv), or single domain antibody, which specifically binds CD138; and a binding region associated with the anchor region, wherein the binding region is capable of binding a specific plasma cell antibody such that the plasma cell is targeted by the individual's immune system for destruction and wherein the binding region comprises an autoantigen selected from the group consisting of nicotinic acetylcholine receptor, muscarinic acetylcholine receptor M1, MuSK protein, myelina associated glycoprotein, 17 hydroxylase, 21 hydroxylase, cardiolipin, .beta.2 glycoprotein I, phosphatidylserine, apoH, annexin A5, voltage-dependent calcium channel, ganglioside D3, ganglioside M1, ganglioside Q1b, thyroid peroxidase, thyroglobulin, glutamate decarboxylase, cyclic citrullinated peptide, IgG-Fc, glycoproteins IIb-IIIa or Ib-IX, ADAMTS13, C1q, complement factor H, and glutamic acid decarboxylase.

2. The method of claim 1 wherein the binding region is capable of binding to a variable region of the specific plasma cell antibody.

3. The method of claim 1 wherein the autoantigen is nicotinic acetylcholine receptor or muscarinic acetylcholine receptor M1.

4. The method of claim 1 wherein the anchor region and the binding region are associated via a linker.

5. The method of claim 1 wherein the anchor region and binding region form part of the same polypeptide.

6. A method for the treatment or prevention of a disease caused or exacerbated by an antibody released by a plasma cell comprising delivering to an individual a nucleic acid encoding a composition comprising: an anchor region, wherein the anchor region is an antibody, a (Fab').sub.2, monovalent Fab, single chain antibody, single chain Fv (scFv), or single domain antibody, which specifically binds CD138 on a plasma cell; and a binding region associated with the anchor region, wherein the binding region is capable of binding a specific plasma cell antibody such that the plasma cell is targeted by the individual's immune system for destruction and wherein the binding region comprises an autoantigen selected from the group consisting of nicotinic acetylcholine receptor, muscarinic acetylcholine receptor M1, MuSK protein, myelina associated glycoprotein, 17 hydroxylase, 21 hydroxylase, cardiolipin, .beta.2 glycoprotein I, phosphatidylserine, apoH, annexin A5, voltage-dependent calcium channel, ganglioside D3, ganglioside M1, ganglioside Q1b, thyroid peroxidase, thyroglobulin, glutamate decarboxylase, cyclic citrullinated peptide, IgG-Fc, glycoproteins IIb-IIIa or Ib-IX, ADAMTS13, C1q, complement factor H, and glutamic acid decarboxylase.

7. The method of claim 6 wherein the nucleic acid is provided in combination with an additional pharmaceutically active agent capable of preventing the regeneration of plasma cells.

8. The method of claim 7, wherein the additional pharmaceutically active agent is an anti-CD20 antibody.

9. The method of claim 8 wherein the anti-CD20 antibody is rituximab, ocrelizumab or ofatumumab.

10. The method of claim 7 wherein the additional pharmaceutically active agent capable of targeting BLyS or APRIL.

11. The method of claim 10 wherein the additional pharmaceutically active agent capable of targeting BLyS is Belivumab.

12. The method of claim 11 wherein the additional pharmaceutically active agent capable of targeting APRIL is Atacicept.

13. The method of claim 6 wherein the individual has been previously subjected to a plasmapheresis treatment to reduce or eliminate serum antibodies.

14. The method of claim 6 wherein the individual is treated with an additional pharmaceutically active agent capable of preventing the regeneration of plasma cells.

15. A method for elimination of an antibody released by a plasma cell comprising delivering to an individual a composition comprising: an anchor region, comprising an antibody, a (Fab').sub.2, monovalent Fab, single chain antibody, single chain Fv (scFv), or single domain antibody, which specifically binds CD138 expressed on a plasma cell; and a binding region associated with the anchor region, wherein the binding region is capable of binding a specific plasma cell antibody such that the plasma cell is targeted by the individual's immune system for destruction and wherein the binding region comprises an autoantigen selected from the group consisting of nicotinic acetylcholine receptor, muscarinic acetylcholine receptor M1, MuSK protein, myelina associated glycoprotein, 17 hydroxylase, 21 hydroxylase, cardiolipin, .beta.2 glycoprotein I, phosphatidylserine, apoH, annexin A5, voltage-dependent calcium channel, ganglioside D3, ganglioside M1, ganglioside Q1b, thyroid peroxidase, thyroglobulin, glutamate decarboxylase, cyclic citrullinated peptide, IgG-Fc, glycoproteins IIb-IIIa or Ib-IX, ADAMTS13, C1q, complement factor H, and glutamic acid decarboxylase.

16. The method of claim 15 wherein said method is carried out in vivo.

17. The method of claim 15 wherein the autoantigen is nicotinic acetylcholine receptor or muscarinic acetylcholine receptor M1.

18. The method of claim 15 wherein the anchor region and the binding region are associated via a linker.

19. The method of claim 15 wherein the anchor region and binding region comprise the same polypeptide.

Details for Patent 9,862,772

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2032-09-07
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 10/26/2009 ⤷  Try a Trial 2032-09-07
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 04/01/2011 ⤷  Try a Trial 2032-09-07
Novartis Pharmaceuticals Corporation KESIMPTA ofatumumab Injection 125326 08/20/2020 ⤷  Try a Trial 2032-09-07
Genentech, Inc. OCREVUS ocrelizumab Injection 761053 03/28/2017 ⤷  Try a Trial 2032-09-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.